Citius Oncology 2/14/2025 Earnings Report

Citius Oncology EPS Results

• Actual EPS: -$0.09
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Citius Oncology Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Citius Oncology Announcement Details

• Date: 2/14/2025
• Time: After Market Closes
• Conference Call Date: N/A
• Conference Call Time: N/A

Citius Oncology (NASDAQ:CTOR) (NASDAQ:CTOR) is a clinical-stage biopharmaceutical company focused on the development and commercialization of targeted cancer therapies. Established as a spin-out from Citius Pharmaceuticals in 2021, the firm leverages proprietary DNA-based therapeutic platforms to create novel oncology agents. Its mission is to address critical unmet needs in solid tumors by advancing candidates that combine precise tumor targeting with innovative mechanisms of action.

The company’s pipeline comprises multiple clinical-stage programs, including a DNA-intercalating small molecule designed to induce tumor cell death, a novel chlorotoxin-derived targeting peptide conjugate aimed at selectively binding and penetrating malignant tissue, and an immune-modulating biologic that activates innate pathways to enhance antitumor responses. These candidates are being evaluated across indications such as glioblastoma, pancreatic cancer and hepatic metastases.

In addition to in-house research and development, Citius Oncology engages in strategic partnerships with academic institutions and contract development organizations to accelerate preclinical and clinical studies. The company has established scalable manufacturing processes compliant with current Good Manufacturing Practices (cGMP) and is pursuing regional collaborations to support regulatory filings and market access in North America and Europe.

The leadership team brings extensive experience from major pharmaceutical and biotechnology companies, with expertise spanning oncology research, clinical development, manufacturing and regulatory affairs. Supported by a scientific advisory board of oncologists and translational researchers, the management team is focused on advancing its pipeline through key clinical milestones and preparing for eventual commercialization.